CRISPR Therapeutics AG (CRSP) Assets Average (2016 - 2026)

CRISPR Therapeutics AG has disclosed Assets Average across 11 years of filings, most recently posting $2.7 billion for Q2 2026.

• In Q2 2026, Assets Average rose 28.14% year-over-year to $2.7 billion; the TTM figure through Jun 2026 stood at $2.7 billion (up 28.14% YoY), while the FY2025 annual figure was $2.3 billion, up 0.8% from the prior year.
• Assets Average came in at $2.7 billion for Q2 2026 at CRISPR Therapeutics AG, up from $2.5 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $2.7 billion in Q2 2026 to a low of $2.1 billion in Q2 2025.
• Average Assets Average over 5 years is $2.3 billion, with a median of $2.3 billion recorded in 2024.
• The largest YoY upside for Assets Average was 41.53% in 2022 against a maximum downside of 17.53% in 2022.
• Over 5 years, Assets Average stood at $2.3 billion in 2022, then fell by 6.09% to $2.2 billion in 2023, then increased by 4.21% to $2.2 billion in 2024, then climbed by 0.28% to $2.3 billion in 2025, then rose by 19.2% to $2.7 billion in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $2.7 billion in Q2 2026, $2.5 billion in Q1 2026, and $2.3 billion in Q4 2025.